Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

10x Genomics (TXG) R&D In Process (2018 - 2020)

10x Genomics (TXG) has disclosed R&D In Process for 2 consecutive years, with $406.9 million as the latest value for Q4 2020.

  • Quarterly R&D In Process changed N/A to $406.9 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $447.5 million through Dec 2021, changed 0.0% year-over-year, with the annual reading at $447.5 million for FY2020, N/A changed from the prior year.
  • R&D In Process hit $406.9 million in Q4 2020 for 10x Genomics, up from $40.6 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $406.9 million in Q4 2020 to a low of $16.1 million in Q3 2018.